MedTrace Logo

The Colitis Once Daily Asacol Study

NCT00708656 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2020-01-30

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800 mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the maintenance of remission of ulcerative colitis.

Conditions

Interventions

DRUG

mesalazine (Asacol®)

800 mg tablets

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • Cardiff and Vale University Health Board

    lead OTHER_GOV

Principal Investigators

  • Dr A B Hawthorne · Cardiff and Vale University Health Board

  • Professor C Probert · Bristol Royal Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-07-31
Completion
2010-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00708656 on ClinicalTrials.gov